CONNECTA THERAPEUTICS SL

CONNECTA therapeutics is a clinical stage biotechnology company committed to developing new therapies for CNS disorders without current treatment options. Our leading program CTH120 is a first-in-class NCE for the treatment of neuroplasticity-mediated disorders where social behaviour and cognition are particularly affected. The first indication for CTH120 is Fragile x syndrome, the most common inherited cause of intellectual disability and a major unmet need.